(Q35067125)

6 August 2017

1 reference

title

Overview of the clinical efficacy of investigational anticancer drugs (English)

1 reference

6 August 2017

2

Larsson R

1 reference

6 August 2017

1

Nygren P

1 reference

PubMed ID

12588538

6 August 2017

language of work or name

English

0 references

publication date

1 January 2003

1 reference

Journal of Internal Medicine

6 August 2017

1 reference

6 August 2017

253

1 reference

6 August 2017

1

1 reference

6 August 2017

46-75

1 reference

6 August 2017

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

What is cancer chemotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Multidrug resistance in cancer: role of ATP-dependent transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Prodrug strategies in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Amifostine in clinical oncology: current use and future applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Gene therapy to protect haematopoietic cells from cytotoxic cancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Apoptosis-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Oncogenic tyrosine kinases and the DNA-damage response

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Novel targets for lung cancer therapy: part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Trastuzumab: hopes and realities

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

NF-kappaB in cancer: from innocent bystander to major culprit

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Cancer gene therapy: fringe or cutting edge?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Antisense therapy in oncology: new hope for an old idea?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

New functions for the matrix metalloproteinases in cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Angiogenesis modulation in cancer research: novel clinical approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Metronomic scheduling: the future of chemotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Improving the efficacy of antibody-based cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Clinical cancer vaccine trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

The use of dendritic cells in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Relationship between objective responses in phase I trials and potential efficacy of non-specific cytotoxic investigational new drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Death and anti-death: tumour resistance to apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Phase I trial of lobradimil (RMP-7) and carboplatin in children with brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Phase II trial of chronomodulated infusion of high-dose fluorouracil and l-folinic acid in previously untreated patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Dolastatin-10 in metastatic melanoma: a phase II and pharmokinetic trial of the California Cancer Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

A phase II pilot study of KW-2189 in patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Chemosensitisation of malignant melanoma by BCL2 antisense therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Surprise phase III failure for ZD1839.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Chronic oral administration of CI-994: a phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Histone deacetylase inhibitors as new cancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

A multicenter phase II study of tgDCC-E1A for the intratumoral treatment of patients with recurrent head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Treatment of acute promyelocytic leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposi's sarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Vinblastine and interferon-gamma combination with and without 13-cis retinoic acid for patients with advanced renal cell carcinoma. Results of two phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Initial clinical trial of oral TAC-101, a novel retinoic acid receptor-alpha selective retinoid, in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Treatment with the novel anti-angiogenic agent PI-88 is associated with immune-mediated thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Soluble E-selectin in cancer patients as a marker of the therapeutic efficacy of CM101, a tumor-inhibiting anti-neovascularization agent, evaluated in phase I clinical trail

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Developing effective cancer vaccines: design and monitoring are critical

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

The biological treatment of renal-cell carcinoma and melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

A phase II study of the bispecific antibody MDX-H210 (anti-HER2 x CD64) with GM-CSF in HER2+ advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Clinical experience with CD64-directed immunotherapy. An overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Selective anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

On the eve of protein destruction: ubiquitin research begins to pay off

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Phase I study of recombinant human endostatin in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Breaking the silence: the rise of epigenetic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Activity of the dolastatin analogue, LU103793, in malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

Meta-analysis of adjuvant immunochemotherapy using OK-432 in patients with resected non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01098.X

10.1046/J.1365-2796.2003.01098.X

21 January 2018

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12588538